Lipo-C Injection vs Tirzepatide
A side-by-side research comparison of Lipo-C Injection and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Lipo-C Injection | Tirzepatide |
|---|---|---|
| Full name | Lipotropic MIC + B12 Injection | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | FDA Approved |
| Mechanism | Methionine provides sulfur for detoxification, inositol supports fat transport from liver, choline emulsifies cholesterol and fat, B12 boosts cellular energy metabolism and red blood cell production. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | Combination compound | 4,814 Da |
| Half-life | Variable by component | 5 days (120 hours) |
| Bioavailability | ~100% IM injection | High (SubQ ~80%) |
| Typical dose | 1 mL | 2.5 mg → titrate up to 15 mg |
| Frequency | 1-2x per week | Once weekly |
| Route | Intramuscular or subcutaneous injection | Subcutaneous injection |
Lipo-C Injection reported benefits
- Enhanced fat metabolism
- Liver support
- Increased energy
- B12 optimization
- Complements weight loss protocols
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.